The True Post (Web News)
Muhammad Aman Ullah
Published: September 2, 2026
Two experimental weight-loss drugs have produced encouraging results in recent research, raising hopes that a new generation of obesity treatments could eventually offer greater weight reduction than some currently available medicines.
The drugs, retatrutide and amycretin, are still under clinical development and are not yet approved as routine treatments for weight loss.
Research has shown substantial reductions in body weight among people receiving the experimental injections. However, experts caution that the results need to be interpreted carefully because the drugs have been studied in different trials, with different treatment periods, doses and participant groups.
Retatrutide Shows Significant Weight Loss
Retatrutide has attracted considerable attention because of the level of weight reduction reported in clinical research.
In a Phase 2 obesity trial, participants receiving the highest dose of retatrutide lost an average of 24.2% of their body weight after 48 weeks. A systematic review of randomized trials subsequently estimated a placebo-subtracted weight reduction of about 22.1% for retatrutide. (New England Journal of Medicine)
The drug works by targeting three hormone pathways—GIP, GLP-1 and glucagon receptors—which researchers believe may contribute to its effects on body weight and metabolism.
The results have made retatrutide one of the most closely watched experimental treatments in the obesity-drug pipeline.
Comparison With Tirzepatide
The new research has also drawn attention because of comparisons with tirzepatide, the active ingredient in medicines such as Mounjaro.
A recent analysis reported that tirzepatide produced approximately 19% weight loss over about 17 months, while retatrutide was associated with around 22.1% weight loss over approximately 48 weeks in the data being compared. (The Independent)
However, these figures should not be interpreted as a direct head-to-head comparison.
The drugs were not necessarily tested under identical conditions, and differences in study design, treatment duration, dosage and patient characteristics can affect the results.
Researchers therefore need properly controlled head-to-head trials before determining whether retatrutide is genuinely more effective than tirzepatide.
Retatrutide Is Still Experimental
Despite its promising results, retatrutide has not yet become an approved routine treatment for obesity.
The drug remains under clinical development, meaning researchers are continuing to evaluate its effectiveness, safety and long-term effects.
Clinical trials have reported gastrointestinal side effects among participants, while increases in heart rate were also observed in the Phase 2 study and were dose-dependent. (New England Journal of Medicine)
This is why strong weight-loss results alone are not enough for a new medicine to receive regulatory approval.
Regulators also examine potential risks, side effects, long-term safety and the overall balance between benefits and risks.
Amycretin Also Produces Encouraging Results
Another experimental drug, amycretin, has also produced significant weight-loss results.
A Phase 1b/2a clinical study examined once-weekly injectable amycretin in adults with overweight or obesity.
According to the published study, participants receiving the highest tested dose achieved an estimated 24.3% reduction in body weight after 36 weeks. A separate 20mg group recorded an estimated 22.0% reduction over the same period. (PubMed)
The results were described as supporting further investigation into amycretin’s potential for weight management.
The study also found that gastrointestinal side effects were among the most common adverse events, with most reported as mild to moderate. (PubMed)
How Amycretin Works
Amycretin is a newer type of obesity medicine designed to act on both the GLP-1 and amylin receptor pathways.
Novo Nordisk, which is developing the drug, has been studying amycretin as a potential treatment for people with overweight or obesity.
In its Phase 1b/2a trial, the company reported estimated weight reductions of 9.7% at 20 weeks with a 1.25mg dose, 16.2% at 28 weeks with a 5mg dose and 22.0% at 36 weeks with a 20mg dose. (Novo Nordisk)
The findings have increased interest in whether medicines targeting multiple biological pathways could provide greater weight reduction than existing treatments.
Comparison With Semaglutide
The new experimental treatments have also been compared with medicines based on semaglutide, including Wegovy and Ozempic.
Recent analyses have reported that semaglutide-based injections can produce substantial weight loss, although the estimated reduction is generally lower than the highest figures reported for retatrutide and amycretin in their respective trials. (DOI)
However, once again, researchers warn that comparing percentages from separate clinical trials can be misleading.
The studies may involve different participants, doses, treatment durations and methods of measuring outcomes.
A direct comparison in the same clinical trial would provide much stronger evidence about which treatment is more effective.
Growing Interest in Weight-Loss Medicines
Obesity and overweight are major health concerns around the world, increasing demand for effective medical treatments.
Medicines based on GLP-1 and related hormone pathways have transformed the weight-management field in recent years.
Treatments containing semaglutide and tirzepatide have become widely known, while researchers are now developing newer drugs that target additional biological pathways.
Retatrutide and amycretin are among the experimental treatments generating significant interest because of the amount of weight loss reported in early clinical studies.
The emerging research suggests that future obesity medicines could potentially produce greater weight reductions than some currently available treatments.
Weight Loss Is Not the Only Measure of Success
Experts emphasize that the success of an obesity medicine cannot be judged solely by the percentage of weight lost.
Researchers must also examine how safely people can use the treatment, how well they tolerate it, what side effects occur and whether weight loss can be maintained over the long term.
For example, gastrointestinal problems have been among the most frequently reported side effects in studies of both retatrutide and amycretin. (New England Journal of Medicine)
Long-term studies are therefore essential before doctors and regulators can determine the full benefits and risks of these medicines.
Experts Call for More Research
Although the results are encouraging, researchers and medical experts caution against treating experimental drugs as established treatments.
Retatrutide and amycretin still require additional clinical research to determine their long-term effectiveness and safety.
Researchers also need to establish whether the significant weight reductions seen in early studies can be maintained over longer periods.
Regulatory authorities will ultimately review the available evidence before deciding whether these medicines should be approved for wider medical use.
Important Warning for Patients
People should not attempt to obtain or use experimental weight-loss medicines on their own.
A drug that produces promising results in a clinical trial is not automatically suitable or safe for everyone.
Patients considering medication for weight management should discuss approved treatment options with a qualified healthcare professional.
The results from experimental trials should also not be interpreted as personal medical advice.
Could These Drugs Change the Future of Obesity Treatment?
The results from retatrutide and amycretin have increased expectations for the next generation of obesity medicines.
Retatrutide has demonstrated weight reductions of more than 20% in clinical research, while amycretin has also produced weight reductions above 20% in certain study groups. (New England Journal of Medicine)
These results are particularly notable because they have been achieved over relatively limited study periods.
However, the findings do not yet establish that either drug is superior to currently approved treatments.
Further trials, particularly longer-term and direct head-to-head studies, will be needed to determine how these medicines compare in terms of effectiveness, safety, tolerability and durability of weight loss.
For now, retatrutide and amycretin remain experimental drugs, but their early results are providing researchers with new possibilities in the treatment of obesity.
